Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry.

Broniarczyk J, Massimi P, Pim D, Bergant Marušič M, Myers MP, Garcea RL, Banks L.

J Virol. 2019 Jun 14;93(13). pii: e00128-19. doi: 10.1128/JVI.00128-19. Print 2019 Jul 1.

PMID:
30996086
2.

Viral replication centers and the DNA damage response in JC virus-infected cells.

Erickson KD, Garcea RL.

Virology. 2019 Feb;528:198-206. doi: 10.1016/j.virol.2018.12.014. Epub 2019 Feb 26.

PMID:
30811999
3.

Murine Polyomavirus Cell Surface Receptors Activate Distinct Signaling Pathways Required for Infection.

O'Hara SD, Garcea RL.

MBio. 2016 Nov 1;7(6). pii: e01836-16. doi: 10.1128/mBio.01836-16.

4.

Activation of DNA damage repair pathways by murine polyomavirus.

Heiser K, Nicholas C, Garcea RL.

Virology. 2016 Oct;497:346-356. doi: 10.1016/j.virol.2016.07.028. Epub 2016 Aug 16.

5.

WU and KI polyomavirus infections in Filipino children with lower respiratory tract disease.

Rao S, Lucero MG, Nohynek H, Tallo V, Lupisan SP, Garcea RL, Simões EAF; ARIVAC Consortium.

J Clin Virol. 2016 Sep;82:112-118. doi: 10.1016/j.jcv.2016.07.013. Epub 2016 Jul 26.

PMID:
27479174
6.

Immunizing against Anogenital Cancer: HPV Vaccines.

Pogoda CS, Roden RB, Garcea RL.

PLoS Pathog. 2016 May 19;12(5):e1005587. doi: 10.1371/journal.ppat.1005587. eCollection 2016 May. Review. No abstract available.

7.

2nd International Conference on Progressive Multifocal Leukoencephalopathy (PML) 2015: JCV virology, progressive multifocal leukoencephalopathy pathogenesis, diagnosis and risk stratification, and new approaches to prevention and treatment.

Patera AC, Butler SL, Cinque P, Clifford DB, Elston R, Garcea RL, Major EO, Pavlovic D, Peterson IS, Ryan AM, Tyler KL, Weber T; PML Consortium.

J Neurovirol. 2015 Dec;21(6):702-5. doi: 10.1007/s13365-015-0392-5. No abstract available.

PMID:
26501778
8.

Ganglioside and Non-ganglioside Mediated Host Responses to the Mouse Polyomavirus.

You J, O'Hara SD, Velupillai P, Castle S, Levery S, Garcea RL, Benjamin T.

PLoS Pathog. 2015 Oct 16;11(10):e1005175. doi: 10.1371/journal.ppat.1005175. eCollection 2015 Oct.

9.

Structural and Functional Analysis of Murine Polyomavirus Capsid Proteins Establish the Determinants of Ligand Recognition and Pathogenicity.

Buch MH, Liaci AM, O'Hara SD, Garcea RL, Neu U, Stehle T.

PLoS Pathog. 2015 Oct 16;11(10):e1005104. doi: 10.1371/journal.ppat.1005104. eCollection 2015 Oct.

10.

Development of a highly thermostable, adjuvanted human papillomavirus vaccine.

Hassett KJ, Meinerz NM, Semmelmann F, Cousins MC, Garcea RL, Randolph TW.

Eur J Pharm Biopharm. 2015 Aug;94:220-8. doi: 10.1016/j.ejpb.2015.05.009. Epub 2015 May 18.

11.

Malawi polyomavirus is a prevalent human virus that interacts with known tumor suppressors.

Berrios C, Jung J, Primi B, Wang M, Pedamallu C, Duke F, Marcelus C, Cheng J, Garcea RL, Meyerson M, DeCaprio JA.

J Virol. 2015 Jan;89(1):857-62. doi: 10.1128/JVI.02328-14. Epub 2014 Oct 15.

12.

Common exposure to STL polyomavirus during childhood.

Lim ES, Meinerz NM, Primi B, Wang D, Garcea RL.

Emerg Infect Dis. 2014 Sep;20(9):1559-61. doi: 10.3201/eid2009.140561.

13.

Structure analysis of the major capsid proteins of human polyomaviruses 6 and 7 reveals an obstructed sialic acid binding site.

Ströh LJ, Neu U, Blaum BS, Buch MH, Garcea RL, Stehle T.

J Virol. 2014 Sep;88(18):10831-9. doi: 10.1128/JVI.01084-14. Epub 2014 Jul 9.

14.

Long-lasting T cell-independent IgG responses require MyD88-mediated pathways and are maintained by high levels of virus persistence.

Raval FM, Mishra R, Garcea RL, Welsh RM, Szomolanyi-Tsuda E.

MBio. 2013 Nov 5;4(6):e00812-13. doi: 10.1128/mBio.00812-13.

15.

A cornucopia of human polyomaviruses.

DeCaprio JA, Garcea RL.

Nat Rev Microbiol. 2013 Apr;11(4):264-76. doi: 10.1038/nrmicro2992. Epub 2013 Mar 11. Review.

16.

Structures of Merkel cell polyomavirus VP1 complexes define a sialic acid binding site required for infection.

Neu U, Hengel H, Blaum BS, Schowalter RM, Macejak D, Gilbert M, Wakarchuk WW, Imamura A, Ando H, Kiso M, Arnberg N, Garcea RL, Peters T, Buck CB, Stehle T.

PLoS Pathog. 2012;8(7):e1002738. doi: 10.1371/journal.ppat.1002738. Epub 2012 Jul 26.

17.

Dynamics of urinary polyomavirus shedding in healthy adult women.

Kling CL, Wright AT, Katz SE, McClure GB, Gardner JS, Williams JT, Meinerz NM, Garcea RL, Vanchiere JA.

J Med Virol. 2012 Sep;84(9):1459-63. doi: 10.1002/jmv.23319.

18.

Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry.

Bienkowska-Haba M, Williams C, Kim SM, Garcea RL, Sapp M.

J Virol. 2012 Sep;86(18):9875-87. doi: 10.1128/JVI.00980-12. Epub 2012 Jul 3.

19.

Dynamics of pregnancy-associated polyomavirus urinary excretion: a prospective longitudinal study.

McClure GB, Gardner JS, Williams JT, Copeland CM, Sylvester SK, Garcea RL, Meinerz NM, Groome LJ, Vanchiere JA.

J Med Virol. 2012 Aug;84(8):1312-22. doi: 10.1002/jmv.23320.

PMID:
22711361
20.

Mutations in the GM1 binding site of simian virus 40 VP1 alter receptor usage and cell tropism.

Magaldi TG, Buch MH, Murata H, Erickson KD, Neu U, Garcea RL, Peden K, Stehle T, DiMaio D.

J Virol. 2012 Jul;86(13):7028-42. doi: 10.1128/JVI.00371-12. Epub 2012 Apr 18.

21.

Virion assembly factories in the nucleus of polyomavirus-infected cells.

Erickson KD, Bouchet-Marquis C, Heiser K, Szomolanyi-Tsuda E, Mishra R, Lamothe B, Hoenger A, Garcea RL.

PLoS Pathog. 2012;8(4):e1002630. doi: 10.1371/journal.ppat.1002630. Epub 2012 Apr 5.

22.

New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.

Gersch ED, Gissmann L, Garcea RL.

Antivir Ther. 2012;17(3):425-34. doi: 10.3851/IMP1941. Epub 2011 Nov 7. Review.

23.

Capsomer vaccines protect mice from vaginal challenge with human papillomavirus.

Wu WH, Gersch E, Kwak K, Jagu S, Karanam B, Huh WK, Garcea RL, Roden RB.

PLoS One. 2011;6(11):e27141. doi: 10.1371/journal.pone.0027141. Epub 2011 Nov 1.

24.

WU and KI polyomavirus infections in pediatric hematology/oncology patients with acute respiratory tract illness.

Rao S, Garcea RL, Robinson CC, Simões EA.

J Clin Virol. 2011 Sep;52(1):28-32. doi: 10.1016/j.jcv.2011.05.024. Epub 2011 Jun 25.

25.

Taxonomical developments in the family Polyomaviridae.

Johne R, Buck CB, Allander T, Atwood WJ, Garcea RL, Imperiale MJ, Major EO, Ramqvist T, Norkin LC.

Arch Virol. 2011 Sep;156(9):1627-34. doi: 10.1007/s00705-011-1008-x. Epub 2011 May 12.

26.

Structures of the major capsid proteins of the human Karolinska Institutet and Washington University polyomaviruses.

Neu U, Wang J, Macejak D, Garcea RL, Stehle T.

J Virol. 2011 Jul;85(14):7384-92. doi: 10.1128/JVI.00382-11. Epub 2011 May 4.

27.

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Jagu S, Kwak K, Garcea RL, Roden RB.

Vaccine. 2010 Jun 17;28(28):4478-86. doi: 10.1016/j.vaccine.2010.04.039. Epub 2010 Apr 29.

28.

Subunit interactions in bovine papillomavirus.

Wolf M, Garcea RL, Grigorieff N, Harrison SC.

Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6298-303. doi: 10.1073/pnas.0914604107. Epub 2010 Mar 22.

29.

Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris.

Bazan SB, de Alencar Muniz Chaves A, Aires KA, Cianciarullo AM, Garcea RL, Ho PL.

Arch Virol. 2009;154(10):1609-17. doi: 10.1007/s00705-009-0484-8. Epub 2009 Sep 10.

30.

Ganglioside GT1b is a putative host cell receptor for the Merkel cell polyomavirus.

Erickson KD, Garcea RL, Tsai B.

J Virol. 2009 Oct;83(19):10275-9. doi: 10.1128/JVI.00949-09. Epub 2009 Jul 15.

31.

Generation of protective T cell-independent antiviral antibody responses in SCID mice reconstituted with follicular or marginal zone B cells.

Guay HM, Mishra R, Garcea RL, Welsh RM, Szomolanyi-Tsuda E.

J Immunol. 2009 Jul 1;183(1):518-23. doi: 10.4049/jimmunol.0900068.

32.

Welcome to the Polyomaviridae.

Dalianis T, Garcea RL.

Semin Cancer Biol. 2009 Aug;19(4):209-10. doi: 10.1016/j.semcancer.2009.04.002. Epub 2009 May 3. No abstract available.

PMID:
19416754
33.

KI, WU and Merkel cell polyomaviruses: a new era for human polyomavirus research.

Dalianis T, Ramqvist T, Andreasson K, Kean JM, Garcea RL.

Semin Cancer Biol. 2009 Aug;19(4):270-5. doi: 10.1016/j.semcancer.2009.04.001. Epub 2009 May 3. Review.

PMID:
19416753
34.

Seroepidemiology of human polyomaviruses.

Kean JM, Rao S, Wang M, Garcea RL.

PLoS Pathog. 2009 Mar;5(3):e1000363. doi: 10.1371/journal.ppat.1000363. Epub 2009 Mar 27.

35.

Possible role for cellular karyopherins in regulating polyomavirus and papillomavirus capsid assembly.

Bird G, O'Donnell M, Moroianu J, Garcea RL.

J Virol. 2008 Oct;82(20):9848-57. doi: 10.1128/JVI.01221-08. Epub 2008 Aug 13.

36.

Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.

Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS.

J Biol Chem. 2007 Oct 26;282(43):31803-11. Epub 2007 Sep 4.

37.

MyD88 is required for the formation of long-term humoral immunity to virus infection.

Guay HM, Andreyeva TA, Garcea RL, Welsh RM, Szomolanyi-Tsuda E.

J Immunol. 2007 Apr 15;178(8):5124-31.

38.

T cell-independent and T cell-dependent immunoglobulin G responses to polyomavirus infection are impaired in complement receptor 2-deficient mice.

Szomolanyi-Tsuda E, Seedhom MO, Carroll MC, Garcea RL.

Virology. 2006 Aug 15;352(1):52-60. Epub 2006 Jun 2.

39.

Chaperone-mediated in vitro disassembly of polyoma- and papillomaviruses.

Chromy LR, Oltman A, Estes PA, Garcea RL.

J Virol. 2006 May;80(10):5086-91.

40.
41.

Virus-like particles as vaccines and vessels for the delivery of small molecules.

Garcea RL, Gissmann L.

Curr Opin Biotechnol. 2004 Dec;15(6):513-7. Review.

PMID:
15560977
42.

In vitro papillomavirus capsid assembly analyzed by light scattering.

Casini GL, Graham D, Heine D, Garcea RL, Wu DT.

Virology. 2004 Aug 1;325(2):320-7.

43.

Lack of serologic evidence for prevalent simian virus 40 infection in humans.

Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor PD, Galloway DA.

J Natl Cancer Inst. 2003 Oct 15;95(20):1522-30.

PMID:
14559874
44.

Chaperone-mediated in vitro assembly of Polyomavirus capsids.

Chromy LR, Pipas JM, Garcea RL.

Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10477-82. Epub 2003 Aug 19.

45.

Simian virus 40 infection of humans.

Garcea RL, Imperiale MJ.

J Virol. 2003 May;77(9):5039-45. No abstract available.

46.

Interactions between papillomavirus L1 and L2 capsid proteins.

Finnen RL, Erickson KD, Chen XS, Garcea RL.

J Virol. 2003 Apr;77(8):4818-26.

47.

Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Müller M, Pawlita M, Schäfer K, Sehr P, Staib C, Sutter G, Gissmann L.

J Virol. 2003 Apr;77(8):4635-45.

48.

SV40: A human pathogen?

Garcea RL.

Dis Markers. 2001;17(3):149-51. Review.

49.

Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.

Malkin D, Chilton-MacNeill S, Meister LA, Sexsmith E, Diller L, Garcea RL.

Oncogene. 2001 Jul 27;20(33):4441-9.

50.

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.

Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, Garcea RL, Schlegel R.

J Virol. 2001 Sep;75(17):7848-53.

Supplemental Content

Loading ...
Support Center